Important Safety Information

Indication

Cathflo Activase (Alteplase) is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood.

Important Safety Information

Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation.

In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis.

Certain causes of catheter dysfunction should be considered before treatment with Cathflo Activase (ie, catheter malposition, mechanical failure, constriction by a suture and lipid deposits or drug precipitates within the catheter lumen).

The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding. Caution should be exercised with patients who have any condition for which bleeding constitutes a significant hazard.

Cathflo Activase should be used with caution in the presence of known or suspected infection in the catheter.

Cathflo is the only lytic

With an efficacy and safety profile in adult and pediatric patients1-4

Indication

Cathflo Activase (Alteplase) is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood.

Important Safety Information

Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation.

In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis.

Certain causes of catheter dysfunction should be considered before treatment with Cathflo Activase (ie, catheter malposition, mechanical failure, constriction by a suture and lipid deposits or drug precipitates within the catheter lumen).

The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding. Caution should be exercised with patients who have any condition for which bleeding constitutes a significant hazard.

Cathflo Activase should be used with caution in the presence of known or suspected infection in the catheter.

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech.
Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control.
Genentech does not recommend and does not endorse the content on any third-party websites.
Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Indication

Cathflo Activase (Alteplase) is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood.

Important Safety Information

Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation.

In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis.

Certain causes of catheter dysfunction should be considered before treatment with Cathflo Activase (ie, catheter malposition, mechanical failure, constriction by a suture and lipid deposits or drug precipitates within the catheter lumen).

The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding. Caution should be exercised with patients who have any condition for which bleeding constitutes a significant hazard.

Cathflo Activase should be used with caution in the presence of known or suspected infection in the catheter.